In Dennis Miller's article "From Xyzal to Zyprexa: Weird Drug Names Proliferate" {https://lnkd.in/eearwwmP}, the recently approved (FDA, EMA, MHRA) antibiotic "#Exblifep" was listed amongst those new products with a "weird" name. But is that really the case? "#Exblifep" [invented & developed through regulatory agency approval by Allecra Therapeutics (France/Germany); marketed in Europe by Advanz Pharma and in Gulf Cooperation Council countries and South Africa by Acino] is a combination of cefepime, a 4th-generation cephalosporin + enmetazobactam, a novel extended-spectrum beta-lactamase inhibitor belonging to the penicillanic acid sulfone family. So if we break down the name, "#Exblifep", it means "out of" ("ex") a "beta-lactamase inhibitor" ("bli") and "cefepime" ("fep", a commonly used abbreviation for this cephalosporin), which is exactly what this new product is.
Business Development In-Licensing Emerging Market at Intas/Accord
4moAmazing strides